5EDI image
Entry Detail
PDB ID:
5EDI
Keywords:
Title:
CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 10 IN COMPLEX WITH c2(c(n1nc(nc1c(c2)C)CCc3nc(nn3C)N4CCCC4)C)Cl, micromolar IC50=0.000279
Biological Source:
Source Organism:
PDB Version:
Deposition Date:
2015-10-21
Release Date:
2016-03-09
Method Details:
Experimental Method:
Resolution:
2.20 Å
R-Value Free:
0.23
R-Value Work:
0.18
R-Value Observed:
0.18
Space Group:
H 3
Macromolecular Entities
Polymer Type:polypeptide(L)
Description:cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A
Chain IDs:A, C, D
Chain Length:319
Number of Molecules:3
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Description:cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A
Chain IDs:B
Chain Length:320
Number of Molecules:1
Biological Source:Homo sapiens
Modified Residue
Compound ID Chain ID Parent Comp ID Details 2D Image
CME A CYS modified residue
Primary Citation

Abstact

We present a series of small molecule drug discovery case studies where computational methods were prospectively employed to impact Roche research projects, with the aim of highlighting those methods that provide real added value. Our brief accounts encompass a broad range of methods and techniques applied to a variety of enzymes and receptors. Most of these are based on judicious application of knowledge about molecular conformations and interactions: filling of lipophilic pockets to gain affinity or selectivity, addition of polar substituents, scaffold hopping, transfer of SAR, conformation analysis, and molecular overlays. A case study of sequence-driven focused screening is presented to illustrate how appropriate preprocessing of information enables effective exploitation of prior knowledge. We conclude that qualitative statements enabling chemists to focus on promising regions of chemical space are often more impactful than quantitative prediction.

Legend

Protein

Chemical

Disease

Primary Citation of related structures